Baylor researchers are part of a monumental national research study that will likely change the approach doctors take for treating diabetes in the future, investigators say.
The study, which is sponsored by the National Institutes of Health (NIH), is called GRADE, Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.
“Diabetes as a disease takes a long time to ‘evolve,’ and while many previous studies looked at the short-term gains in blood sugar control, there has been a major need for studies that follow long-term complications, side effects and the cost and quality of life issues with these medicines,” said Principal Investigator Priscilla Hollander, M.D., of the Baylor Endocrine Center, an affiliate of Baylor Research Institute. “Information from this study will help patients and their doctors for years, and perhaps decades, to come.”
Type 2 diabetes affects 24.5 million Americans, whose risk of cardiovascular disease is two to five times higher than people without the condition.
“With so many new diabetes drugs coming on the market over a relatively brief time period,” said investigator Erin D. Roe, M.D., “doctors and patients lack impartial, head-to-head trial data comparing these medications over an extended period of time.”
The two Dallas doctors are currently recruiting 150 patients who were diagnosed with type 2 diabetes in the past five years and who are taking only metformin, but are willing to try more intensive treatment, including insulin.
Among the most positive aspects of the study from the patient’s perspective, they said, is that it doesn’t involve experimental drugs, and there’s no chance of receiving a placebo.
Participants also will receive related doctor visits and medications at no charge.
To find out more, call the Endocrine Center’s research hotline at 214.820.4774.